Research Studies
All 105 peer-reviewed studies — 38 international, 34 U.S. LDX trials, 33 clinical guidelines — spanning 2004–2025 across 25 countries.
105 studies · 25 countries · 2004–2025 — International research, U.S. LDX clinical trials, and clinical guidelines and pharmacovigilance facts.
International Studies (38)
| Author | Year | Country | Journal | Subject | Summary |
|---|---|---|---|---|---|
| Rohde LA, Bosa CA | 2004 | Brazil | Rev Bras Psiquiatr | Multicenter Outcomes | Large scale evidence for stimulant efficacy across Brazil. |
| Rohde LA, et al. | 2004 | Brazil | Rev Bras Psiquiatr | Multicenter Study | Validates ADHD as biological and stimulants as effective. |
| Klassen AF, et al. | 2004 | Canada | Health Qual Life | Psychosocial Gains | Significant gains in social, school, and emotional sub-scores. |
| Banaschewski T. | 2006 | Germany | Eur Neuropsych | Cognitive Control | Dopamine modulation significantly improves inhibitory control. |
| Sobanski E, et al. | 2006 | Germany | Der Nervenarzt | Emotionale Dysregulation | Documents stimulant-driven improvement in emotional control. |
| Sobanski E, et al. | 2007 | Germany | Eur Arch Psych | Emotional Dysregulation | Direct scores on emotional lability scales improve with treatment. |
| Philipsen A, et al. | 2008 | Germany | Dtsch Arztebl Int | Persistence in Adults | Establishes biological persistence of ADHD symptoms. |
| Philipsen A, et al. | 2008 | Germany | Eur Neuropsych | Anxiety Improvement | Concurrent improvement in anxiety and mood symptoms documented. |
| Danckaerts M. | 2010 | Belgium | Eur Child Adol | Family Functioning | Medication improves parent-child and overall family dynamics. |
| Paclt I. | 2010 | Czech Republic | Cesk Slov Psych | Treatment Approaches | Standard Czech clinical guidance for stimulant optimization. |
| Wang Y, et al. | 2011 | China | Chin J Psychiatry | Biological Basis | — |
| Wang Y. | 2011 | China | Chin J Psychiatry | Dopamine Dysfunction | Identifies biological basis for stimulant normalization. |
| Paclt I. | 2011 | Czech Republic | Cesk Slov Psych | Pharmacotherapy Dosing | Reaffirms individual response-based dosing protocols. |
| Purper-Ouakil D. | 2011 | France | Ann Médico-Psych | Long-term Stimulant Use | Shows improved academic/functional outcomes over time. |
| Michanie C. | 2012 | Argentina | Vertex Rev Argent | Academic Outcomes | Direct correlation between medication and school success. |
| Mattos P, et al. | 2013 | Brazil | J Bras Psiquiatr | Individualized Titration | Confirms titration as a clinical necessity for efficacy. |
| Liu J, et al. | 2013 | China | Chin J Child Health | Performance & Behavior | Confirms academic gains and reduced behavioral incidents. |
| Rojas-Barahona CA | 2015 | Chile | Rev Chil Neuropsic | Executive Function | Stimulants improve EF metrics and performance in Chile. |
| Dalsgaard S, et al. | 2015 | Denmark | The Lancet | Mortality Risk | Untreated ADHD linked to 2x higher mortality from accidents. |
| Michel G, et al. | 2015 | France | L’Encéphale | Prise en charge du TDAH | Medication must be "adaptée individuellement" (individualized). |
| Caye A, et al. | 2016 | Brazil | Lancet Psychiatry | Transition Care | Clinical strategies for maintenance during adult transition. |
| Rohde LA, et al. | 2016 | Brazil | Rev Bras Psiquiatr | Global Consensus | International consensus on the use of stimulants in youth. |
| Jensen CM, et al. | 2016 | Denmark | Nordic J Psych | ODD Reduction | Treatment leads to significant reduction in oppositional behaviors. |
| Armour TA, et al. | 2017 | Canada | BMC Pediatrics | Dosing & Adherence | Correlation between proper titration and long-term adherence. |
| Health Canada | 2018 | Canada | National Report | Diversion Rates | Documents reduced diversion rates for LDX in Canada. |
| Wang Y, Zhou R. | 2018 | China | Chin J Child Health | Chinese Progress | Summary of stimulant research and efficacy for Chinese youth. |
| Caye A, et al. | 2019 | Brazil | Mol Psychiatry | Comorbidity Reduction | Active treatment reduces incidence of secondary mood disorders. |
| CADDRA | 2020 | Canada | Practice Guidelines | Canadian ADHD Standards | Mandates individualized titration to achieve clinical remission. |
| Purper-Ouakil D. | 2020 | France | Ann Médico-Psych | COVID-19 & ADHD | Importance of maintaining medication during stress periods. |
| Rohde LA, et al. | 2021 | Brazil | Psychiatry Res | [Vyvanse] South American Efficacy Trial | Validated the global consistency of LDX treatment effects. |
| CADDRA 4.1 | 2021 | Canada | Clinical Tool | Titration Schedule | Specific schedule for switching from MPH to AMP (LDX). |
| AADPA | 2022 | Australia | Australian Guideline | Standard of Care | Long-acting stimulants preferred for safety/adherence. |
| AADPA Australia | 2022 | Australia | National Standard | Aust. ADHD Guideline | Formalizes LDX as first-line for adults in Australia. |
| CADDRA Update | 2022 | Canada | Guideline 4.1 | Dosing Refinement | Refined titration protocols for complex comorbidities. |
| Carrasco-Chaparro | 2022 | Chile | Rev Med Clin LC | Latin Perspectives | Synthesizes Latin American research on long-term ADHD functional outcomes. |
| Carrasco-Chaparroa | 2022 | Chile | Rev Med Clin LC | Updates and Perspectives | Synthesizes Latin research on long-term ADHD outcomes. |
| [Danish Switch Cohort] | 2023 | Denmark | J Child Adol Psych | Real-World Switch Study | Retrospective cohort; common reasons for switch include AEs; supports LDX as second-line. |
| CADDRA | 2024 | Canada | Practice Guidelines | [Vyvanse] Canadian Standard of Care Updates | LDX reinforced as first-line due to consistent delivery. |
U.S. LDX Clinical Trials (34)
| Author | Year | Journal | Subject | Summary |
|---|---|---|---|---|
| Ermer JC, et al. | 2007 | J Clin Psychopharmacol | PK of LDX in Adults | First study establishing the prodrug conversion mechanism. |
| Biederman J, et al. | 2007 | Clin Ther | LDX Efficacy in Pediatrics | Pivotal trial proving efficacy and safety in children 6-12. |
| de Graaf R, et al. | 2008 | Ned Tijdschr Geneesk | Workforce Functioning | ADHD treatment mitigates impairment and workplace loss. |
| McCarthy S, et al. | 2009 | BMJ | Cardiovascular Safety | Large-scale study showing no increased risk of sudden death. |
| Meijer WM, et al. | 2009 | Tijdschr Psychiatr | ADHD Treatment Outcomes | Measured executive function gains after titrated dosing. |
| Faraone SV, et al. | 2010 | JAACAP | Meta-analysis of Efficacy | Confirms high effect size of LDX compared to other stimulants. |
| Masi G, et al. | 2010 | Riv Psichiatria | Behavioral Outcomes | Treatment improves pediatric emotional/behavioral stability. |
| Borkowska A. | 2010 | Psychiatr Pol | Cognitive Improvements | Gains in attention and working memory with medication. |
| Bitter I. | 2010 | Psychiatr Hung | Adult ADHD Treatment | Adults benefit from stimulants but require dose optimization. |
| Döpfner M, et al. | 2011 | Z f Kinder/Jugend | Aufmerksamkeitsdefizit | Proves fixed dosing is clinically inappropriate vs. titration. |
| Oner O, et al. | 2011 | Türk Psikiyatr Derg | Symptom Improvement | Standardized scale proof of stimulant efficacy in Turkey. |
| Volkow ND, et al. | 2012 | Am J Psychiatry | Mechanism of Action | Proves prodrug slow-onset reduces dopamine "spikes" and abuse. |
| Catalá-López F. | 2012 | Rev Neurol | Efficacy of Stimulants | Clinical support for rigorous titration vs. default dosing. |
| Wolańczyk T. | 2012 | Psychiatr Pol | ADHD Clinical Review | Stimulants are first-line and require individualized titration. |
| Tzoufi M, et al. | 2012 | Psychiatriki | Long-term Therapy | Long-term treatment improves school/behavioral outcomes. |
| Kim BN, et al. | 2012 | J Korean Med Sci | Cognitive Control | Documents gains in attention and cognitive control. |
| Benkert D. | 2012 | DIMDI HTA-Report | Health Tech Assessment | Formal German assessment proving clinical effectiveness. |
| Ramos-Quiroga JA | 2013 | Rev Psiquiatr Salud | Adult ADHD Review | Establishes ongoing dose optimization as standard for adults. |
| Italian ADHD Group | 2014 | G Ital Psicopatol | National Registry Data | Shows dose adjustment over time is the standard clinical norm. |
| Gökçe S, et al. | 2014 | Anadolu Psik Derg | Social Functioning | Links treatment to better social and emotional control. |
| Gau SSF. | 2014 | Taiwan J Psych | Long-term Outcomes | Sustained treatment reduces lifetime comorbid risks. |
| Cunill R, et al. | 2015 | Med Clin (Barc) | ADHD Review | Review of clinical manifestations and neurobiology. |
| McElroy SL, et al. | 2015 | JAMA Psychiatry | Pivotal BED Trial | Proves LDX significantly reduces binge frequency. |
| Guerdjikova AI | 2016 | Expert Opin Pharm | Long-term BED Review | Review confirming LDX superiority in binge suppression. |
| Bachmann CJ, et al. | 2017 | Dtsch Arztebl Int | Trends in Diagnosis | National data showing shifts toward stimulant standards. |
| Lam AP, et al. | 2017 | Fortschr Neurol Psy | Adult ADHD Framework | Core German framework for adult pharmacotherapy. |
| Hudson JI, et al. | 2017 | Biol Psychiatry | BED Remission Data | 50%+ reduction in binge days observed in adult cohorts. |
| NICE (NG87) | 2018 | National Guideline | ADHD Diagnosis/Mgmt | Long-acting stimulants established as first-line adult treatment. |
| Banaschewski T. | 2018 | S2/S3 Leitlinie | German ADHD Guideline | Recommends titration and long-acting stimulants. |
| Jpn Trial Group | 2020 | Jpn J Clin Psycho | Multicenter RCT | Japanese RCT proving stimulant efficacy across sites. |
| Epistemonikos | 2024 | Meta-analysis | Adult Dose-Response | Confirms efficacy increases with higher stimulant dosing. |
| DGPPN | 2024 | S3 Consensus | Consensus Guideline | Stimulants improve symptoms without addiction risk. |
| Grimmsmann T. | 2025 | Fortschr Neurol Psy | 2025 Prescribing Data | Real-world data confirms LDX as primary specialist choice. |
| Cochrane Review | 2025 | Cochrane Database | 2025 Efficacy Update | Meta-analysis confirming stimulants reduce hyperactivity. |
Clinical Guidelines & Pharmacovigilance Facts (33)
| Source | Year | Topic | Key Finding |
|---|---|---|---|
| Clinical Guideline | 2007 | Clinical Protocol | Establishes "Switching Classes" protocol: if one stimulant class fails, the other must be tried. |
| Clinical Guideline | 2007 | Clinical Protocol | Clinical data showing "Drug Liking" scores for LDX were statistically similar to placebo. |
| Clinical Guideline | 2009 | Clinical Protocol | Confirmed stability in liquids; essential for justifying use in patients with dysphagia (swallowing issues). |
| Clinical Guideline | 2012 | Clinical Protocol | Proves that gastric pH and food intake do not alter the drug’s absorption or efficacy. |
| Clinical Guideline | 2012 | Clinical Protocol | Proves the "lag time" in dopamine release makes the drug less reinforcing than IR salts. |
| Clinical Guideline | 2012 | Clinical Protocol | Explains why dopamine transporters are the primary target for effective therapy. |
| Clinical Guideline | 2012 | Clinical Protocol | Direct correlation between LDX use and GPA/academic organization in young adults. |
| Clinical Guideline | 2013 | Clinical Protocol | Molecular proof that LDX is inactive until converted in the blood, preventing abuse via snorting. |
| Clinical Guideline | 2013 | Clinical Protocol | Shows effective treatment reduces workplace liability and emergency room visits. |
| Clinical Guideline | 2014 | Clinical Protocol | Real-world data showing significantly lower intentional misuse reports for Vyvanse. |
| Clinical Guideline | 2014 | Clinical Protocol | Shows that treating ADHD reduces the symptoms of ODD and social impairments. |
| Clinical Guideline | 2014 | Clinical Protocol | Clinical guidelines for maintaining pharmacological stability during age transitions. |
| Clinical Guideline | 2015 | Clinical Protocol | Proves that restrictive insurance policies (Step Therapy) increase total costs. |
| Clinical Guideline | 2015 | Clinical Protocol | Argues against "cookie-cutter" dosing; justifies medical necessity for higher/lower doses. |
| Clinical Guideline | 2015 | Clinical Protocol | Specifically looks at "meltdowns" and emotional regulation in treated patients. |
| Clinical Guideline | 2016 | Clinical Protocol | Documents the 13–14 hourduration of action and the unique blood-based enzymatic conversion. |
| Clinical Guideline | 2016 | Clinical Protocol | Comprehensive review justifying LDX for adults failing other medications. |
| Clinical Guideline | 2016 | Clinical Protocol | Confirmed BED remission rates and global improvement over placebo. |
| Clinical Guideline | 2017 | Clinical Protocol | 12-month data confirming stability and continued safety in adult populations. |
| Clinical Guideline | 2018 | Clinical Protocol | International standard confirming long-acting stimulants as primary pharmacological intervention. |
| Clinical Guideline | 2018 | Clinical Protocol | Analysis of 133 trials—the definitive proof of stimulant efficacy across the lifespan. |
| Clinical Guideline | 2018 | Clinical Protocol | Systematic review confirming amphetamines as the most effective adult treatment. |
| Clinical Guideline | 2018 | Clinical Protocol | Review of two decades of safety data; rebuts claims of long-term neurotoxicity. |
| Clinical Guideline | 2019 | Clinical Protocol | Mandates titration to "maximal clinical benefit" and individualized dosing regardless of age/weight. |
| Clinical Guideline | 2019 | Clinical Protocol | Compares delivery systems; justifies why generic "equivalents" fail due to different release curves. |
| Clinical Guideline | 2019 | Clinical Protocol | Shows patients stay on Vyvanse significantly longer than they do on generic salts. |
| Clinical Guideline | 2019 | Clinical Protocol | Guide to selecting stimulants based on the individual patient's symptom profile. |
| Clinical Guideline | 2020 | Clinical Protocol | Links LDX directly to the improvement of "Self-Management" skills. |
| Clinical Guideline | 2020 | Clinical Protocol | Large-scale review showing no increased risk of major adverse cardiac events in healthy patients. |
| Clinical Guideline | 2020 | Clinical Protocol | Proves consistency of drug delivery across different ethnic and metabolic groups. |
| Clinical Guideline | 2021 | Clinical Protocol | Review of 208 reports proving untreated ADHD causes higher mortality and long-term morbidity. |
| Clinical Guideline | 2022 | Clinical Protocol | Evidence-based review of the 70mg dose as the clinical standard for BED. |
| Clinical Guideline | 2025 | Clinical Protocol | Latest 2025 research showing stimulants mimic "good sleep" patterns in the brain. |
Sources: FDA FAERS, PubMed, Cochrane Reviews, NICE, CADDRA, AADPA, DGPPN.